title: Reply to the letter to the editor 'Surrogate end points for overall survival. Festina lente (more haste, less speed)' by Braillon.
authors.affiliation: Graduate School of Pharmaceutical Sciences, Keio University, Tokyo; Clinical Development, Astellas Pharma, Inc., Tokyo, Japan. Electronic address: hideki.maeda@astellas.com.
authors.forename: H
authors.initials: H
authors.lastname: Maeda
authors.affiliation: Graduate School of Pharmaceutical Sciences, Keio University, Tokyo.
authors.forename: T
authors.initials: T
authors.lastname: Kurokawa
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015415:Biomarkers; D017277:Drug Approval; D004341:Drug Evaluation; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers